The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
A role for proteoglycans in vascular disease
Open accessAbstract
The content of proteoglycans (PGs) is low in the extracellular matrix (ECM) of vascular tissue, but increases dramatically in all phases of vascular disease. Early studies demonstrated that glycosaminoglycans (GAGs) including chondroitin sulfate (CS), dermatan sulfate (DS), keratan sulfate (KS) and heparan sulfate (HS) accumulate in vascular lesions in both humans and in animal models in areas of the vasculature that are susceptible to disease initiation (such as at branch points) and are frequently coincident with lipid deposits. Later studies showed the GAGs were covalently attached to specific types of core proteins that accumulate in vascular lesions. These molecules include versican (CSPG), biglycan and decorin (DS/CSPGs), lumican and fibromodulin (KSPGs) and perlecan (HSPG), although other types of PGs are present, but in lesser quantities. While the overall molecular design of these macromolecules is similar, there is tremendous structural diversity among the different PG families creating multiple forms that have selective roles in critical events that form the basis of vascular disease. PGs interact with a variety of different molecules involved in disease pathogenesis. For example, PGs bind and trap serum components that accumulate in vascular lesions such as lipoproteins, amyloid, calcium, and clotting factors. PGs interact with other ECM components and regulate, in part, ECM assembly and turnover. PGs interact with cells within the lesion and alter the phenotypes of both resident cells and cells that invade the lesion from the circulation. A number of therapeutic strategies have been developed to target specific PGs involved in key pathways that promote vascular disease. This review will provide a historical perspective of this field of research and then highlight some of the evidence that defines the involvement of PGs and their roles in the pathogenesis of vascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tabas, I., Williams, K. J., & Borén, J. (2007) · Circulation · doi:10.1161/circulationaha.106.676890 · Cited by 1,399
Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis
Kim, S., Takahashi, H., Lin, W.-W., Descargues, P., Grivennikov, S., Kim, Y., Luo, J.-L., & Karin, M. (2009) · Nature · doi:10.1038/nature07623 · Cited by 1,100
Subendothelial retention of atherogenic lipoproteins in early atherosclerosis
Skålén, K., Gustafsson, M., Rydberg, E. K., Hultén, L. M., Wiklund, O., Innerarity, T. L., & Borén, J. (2002) · Nature · doi:10.1038/nature00804 · Cited by 1,019
Schaefer, L., Babelova, A., Kiss, E., Hausser, H.-J., Baliova, M., Krzyzankova, M., Marsche, G., Young, M. F., Mihalik, D., Götte, M., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23755 · Cited by 850
Taylor, K. R., & Gallo, R. L. (2006) · The FASEB Journal · doi:10.1096/fj.05-4682rev · Cited by 639
Yahagi, K., Kolodgie, F. D., Lutter, C., Mori, H., Romero, M. E., Finn, A. V., & Virmani, R. (2017) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.116.306256 · Cited by 573
Pathophysiology of native coronary, vein graft, and in-stent atherosclerosis
Yahagi, K., Kolodgie, F. D., Otsuka, F., Finn, A. V., Davis, H. R., Joner, M., & Virmani, R. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.164 · Cited by 548 · cited 1×
“Restenotic lesions can also develop into atherosclerosis, involving lipid accumulation at an accelerated rate leading to late-stage stent failure and the need for additional surgery [34, 37, 38].”
BackgroundBasement membrane proteoglycans: from cellar to ceiling
Iozzo, R. V. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1702 · Cited by 521
Hyaluronan, a Crucial Regulator of Inflammation
Petrey, A. C., & de la Motte, C. A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00101 · Cited by 514
Association of HTRA1 Mutations and Familial Ischemic Cerebral Small-Vessel Disease
Hara, K., Shiga, A., Fukutake, T., Nozaki, H., Miyashita, A., Yokoseki, A., Kawata, H., Koyama, A., Arima, K., Takahashi, T., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0801560 · Cited by 460
Inflammation and Immunity in Diseases of the Arterial Tree: Players and Layers
Libby, P., & Hansson, G. K. (2015) · Circulation Research · doi:10.1161/circresaha.116.301313 · Cited by 372
Kolodgie, F. D., Burke, A. P., Farb, A., Weber, D. K., Kutys, R., Wight, T. N., & Virmani, R. (2002) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000034021.92658.4c · Cited by 286
Self-citationde la Motte, C. A., Hascall, V. C., Calabro, A., Yen-Lieberman, B., & Strong, S. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.43.30747 · Cited by 189
Mahley, R. W., & Huang, Y. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30889 · Cited by 159
Acidification of the intimal fluid: the perfect storm for atherogenesis
Öörni, K., Rajamäki, K., Nguyen, S. D., Lähdesmäki, K., Plihtari, R., Lee-Rueckert, M., & Kovanen, P. T. (2015) · Journal of Lipid Research · doi:10.1194/jlr.r050252 · Cited by 101
Jones, P. J. H., MacKay, D. S., Senanayake, V. K., Pu, S., Jenkins, D. J. A., Connelly, P. W., Lamarche, B., Couture, P., Kris-Etherton, P. M., West, S. G., et al. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.12.010 · Cited by 56
Glycosaminoglycan-lipoprotein interaction
Olsson, U., Östergren-Lundén, G., & Moses, J. (2001) · Glycoconjugate Journal · doi:10.1023/a:1021155518464 · Cited by 46
Increased atherosclerosis in mice with increased vascular biglycan content
Thompson, J. C., Tang, T., Wilson, P. G., Yoder, M. H., & Tannock, L. R. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.03.037 · Cited by 45
Antiatherosclerotic Effect of an Antibody That Binds to Extracellular Matrix Glycosaminoglycans
Soto, Y., Acosta, E., Delgado, L., Pérez, A., Falcón, V., Bécquer, M. A., Fraga, Á., Brito, V., Álvarez, I., Griñán, T., et al. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.238659 · Cited by 41
Cited by
Hyaluronan biology: A complex balancing act of structure, function, location and context
Garantziotis, S., & Savani, R. C. (2019) · Matrix Biology · doi:10.1016/j.matbio.2019.02.002 · Cited by 386
Healthy aging and the blood–brain barrier
Banks, W. A., Reed, M. J., Logsdon, A. F., Rhea, E. M., & Erickson, M. A. (2021) · Nature Aging · doi:10.1038/s43587-021-00043-5 · Cited by 292
Versican—A Critical Extracellular Matrix Regulator of Immunity and Inflammation
Wight, T. N., Kang, I., Evanko, S. P., Harten, I. A., Chang, M. Y., Pearce, O. M. T., Allen, C. E., & Frevert, C. W. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00512 · Cited by 268
Self-citationExtracellular matrix dynamics in vascular remodeling
Ma, Z., Mao, C., Jia, Y., Fu, Y., & Kong, W. (2020) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00147.2020 · Cited by 129
Metadata
- Authors
- Wight, T. N.
- Venue
- Matrix Biology
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 71-72
- Pages
- 396-420
- ISSN
- 0945-053X (ISSN-L)
- OpenAlex
- W2790164154
- Cited by
- 160
- References
- 19
- FWCI
- 7.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.